Pharmaceuticals - Research and Markets - RSS Feed

Mapping the Healthcare Landscape: Bringing Pharmaceuticals into Focus

press@researchandmarkets.com — Fri, 27 Nov 2009 15:21:07 GMT

Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration.

Scope

- Analysis of Big Pharma's current business model, and the mergers, acquisitions and divestments which have shaped it.

- Classification of the human and animal healthcare landscape.

- Analysis of ten healthcare sectors using market size, operating margin, and indicative profit potential.

- Assessment of the healthcare landscape, with key recommendations for pharma companies looking to make future M&A decisions.

Highlights of this title

The average operating margin of pharma-focused companies tends to be higher than that of those with a more diversified business model, implying that increasing pharma-focus is the best strategy to drive profit growth.

Both the market size and operating margin associated with pharmaceuticals makes it the most rewarding of all ten healthcare sectors under analysis, and suggests that diversification on the part of Big Pharma will tend to end in profit dilution.

Patents are key to the high rewards associated with pharmaceuticals, and are also responsible for making the medical device/diagnostics sector the third most attractive sector under analysis, with branding playing a similar role for consumer/over-the-counter health.

Key reasons to purchase this title

- Understand how Big Pharma's business model has evolved, and how this has impacted on operating margin.

- Identify the major sectors within the healthcare landscape, and understand how they relate to one-another.

- Analyze the attractiveness of each sector as a target to diversify into, based on market size, operating profit, and indicative profit potential.

KeywordPharma Conference Insights - European CME Forum: First Annual Meeting

press@researchandmarkets.com — Fri, 27 Nov 2009 12:56:51 GMT

This is an in-depth report from a meeting held in London, UK, 4–5 November 2008 The European landscape for continuing medical education (CME) is diverse and complex The absence of a common framework across the region has led to individual countries developing their own national objectives and...

Latin American Pharmaceutical Market Outlook To 2014: Policy Environment, Market Analysis, Forecasts and Growth Opportunities

press@researchandmarkets.com — Thu, 26 Nov 2009 16:37:10 GMT

The $28 8bn Latin American market delivered 15 3% y-o-y growth in 2008 as per IMS Health data The market is expected to grow to $51 3bn in 2014 at a CAGR of 10 1% Inconsistency in regulatory protocol in the seven major Latin American countries – Brazil, Mexico, Venezuela, Argentina, Colombia, Chile...

Snapshots Venezuela Pharmaceuticals 2009

press@researchandmarkets.com — Thu, 26 Nov 2009 15:34:39 GMT

Snapshots Venezuela Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Venezuelan pharmaceutical market and covers prescription medication and OTC pharmaceuticals. Market size is based on retail sales. The data is supplied in both graphical and tabular format for ease of interpretation and analysis. The Snapshots Venezuela Pharmaceuticals 2009 forms part of Pharmaceuticals industry coverage.

Snapshots US Pharmaceuticals 2009